Adaptive Biotechnologies and Collaborators to Present 5 Studies Demonstrating Utility of Immunosequencing to Determine T-cell Function in Chronic and Infectious Diseases at the 2015 American Association of Immunologists Annual Meeting
May 8, 2015
Data on High-Throughput Pairing of T-cell Receptor Alpha and Beta Sequences to be Presented
Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment
May 6, 2015
SEATTLE, WA – Adaptive Biotechnologies, a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives.
Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin’s Lymphoma in Blood
April 28, 2015
SEATTLE, WA - Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center showing that the company’s next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with classical Hodgkin’s lymphoma (CHL).
Harlan Robins, PhD, Featured Speaker at The 2015 Governor's Conference on Effective Partnering in Cancer Research
April 24, 2015
Adaptive’s Chief Scientific Officer and co-Founder, Harlan Robins, PhD, was a featured speaker at The 2015 Governor's Conference on Effective Partnering in Cancer Research, held at Princeton’s Institute for Advanced Study on April 23, 2015. Dr. Robins described the uses of immunosequencing in immunotherapy.
Adaptive Biotechnologies’ clonoSEQ Minimal Residual Disease Test Detects Relapse with Higher Specificity than PET/CT in Diffuse Large B-Cell Lymphoma Patients
April 22, 2015
SEATTLE, WA – Adaptive Biotechnologies today announced the recent publication of a study demonstrating that analysis of circulating tumor DNA (ctDNA) using the company’s next-generation sequencing-based minimal residual disease detection and quantification method (clinically-available as the clonoSEQ™ MRD test) can detect relapse in diffuse large B-cell lymphoma (DLBCL) patients with significantly higher specificity than positron emission tomography combined with CT (PET/CT).
The New York Times reports on the recent advancements in liquid biopsy research, which suggest this kind of test could be an alternative to current methods for evaluating treatment response and monitoring disease status. The report also highlights the recent study published in Lancet Oncology, which showed that analysis of circulating tumor DNA using Adaptive’s clonoSEQ™ MRD test predicted relapse in patients with diffuse large B-cell lymphoma (DLBCL).
Adaptive Biotechnologies and Collaborators to Present 4 Studies Demonstrating Clinical Relevance of Immunosequencing in the Treatment of Solid Tumors at the 2015 American Association for Cancer Research Annual Meeting
April 15, 2015
Seattle, WA – Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present data demonstrating how profiling a patient’s T-cell repertoire may inform clinical care in patients with melanoma and other solid tumors at the American Association for Cancer Research® (AACR) meeting in Philadelphia from April 18-22, 2015.